Back to Search
Start Over
AVPC Molecular Signature Supplementary Tables 1-10 from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- SUPPLEMENTARY TABLE 1. AVPC ('ANAPLASTIC') ELIGIBILITY CRITERIA FOR NCT00514540, A PHASE II STUDY OF CARBOPLATIN AND DOCETAXEL IN PATIENTS WITH ANAPLASTIC PROSTATE CARCINOMA. SUPPLEMENTARY TABLE 2. CLINICOPATHOLOGICAL FEATURES OF THE PDX DONOR PATIENTS. SUPPLEMENTARY TABLE 3. PDX GROWTH RATE AND PSA PRODUCTION. SUPPLEMENTARY TABLE 4. ANTIBODIES USED FOR IMMUNOHISTOCHEMISTRY AND WESTERN BLOT. SUPPLEMENTARY TABLE 5. qRT-PCR PRIMER SEQUENCES. SUPPLEMENTARY TABLE 6. DONOR PATIENT CHARACTERISTICS. SUPPLEMENTARY TABLE 7. SERUM MARKER LEVELS AT TIME OF REGISTRATION TO NCT00514540. SUPPLEMENTARY TABLE 8. PRINCIPAL COMPONENT VARIATE WEIGHTINGS TCGA/UNSELECTED CRPC/AVPC SAMPLES. SUPPLEMENTARY TABLE 9. LINEAR DISCRIMINANT ANALYSIS WEIGHTS. SUPPLEMENTARY TABLE 10. Tp53 MUTATIONS DETECTED IN TCGA, UNSELECTED CRPC (21) AND AVPC SAMPLES.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....9767387765eea68d00438dbe2a2c7d05